DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas. / Loo, Suet Kee; Ch'ng, Ewe Seng; Lawrie, Charles H; Muruzabal, María Arestin; Gaafar, Ayman; Pomposo, María Puente; Husin, Azlan; Md Salleh, Md Salzihan; Banham, Alison H; Pedersen, Lars M; Møller, Michael B; Green, Tina M; Wong, Kah Keng.
In: Pathology, Vol. 49, No. 7, 2017, p. 731-739.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas
AU - Loo, Suet Kee
AU - Ch'ng, Ewe Seng
AU - Lawrie, Charles H
AU - Muruzabal, María Arestin
AU - Gaafar, Ayman
AU - Pomposo, María Puente
AU - Husin, Azlan
AU - Md Salleh, Md Salzihan
AU - Banham, Alison H
AU - Pedersen, Lars M
AU - Møller, Michael B
AU - Green, Tina M
AU - Wong, Kah Keng
N1 - Crown Copyright © 2017. Published by Elsevier B.V. All rights reserved.
PY - 2017
Y1 - 2017
N2 - DNMT1 is a target of approved anti-cancer drugs including decitabine. However, the prognostic value of DNMT1 protein expression in R-CHOP-treated diffuse large B-cell lymphomas (DLBCLs) remains unexplored. Here we showed that DNMT1 was expressed in the majority of DLBCL cases (n = 209/230, 90.9%) with higher expression in germinal centre B-cell-like (GCB)-DLBCL subtype. Low and negative DNMT1 expression (20% cut-off, n = 33/230, 14.3%) was predictive of worse overall survival (OS; p < 0.001) and progression-free survival (PFS; p < 0.001). Nonetheless, of the 209 DNMT1 positive patients, 33% and 42% did not achieve 5-year OS and PFS, respectively, indicating that DNMT1 positive patients showed considerably heterogeneous outcomes. Moreover, DNMT1 was frequently expressed in mitotic cells and significantly correlated with Ki-67 or BCL6 expression (r = 0.60 or 0.44, respectively; p < 0.001). We demonstrate that DNMT1 is predictive of DLBCL patients' survival, and suggest that DNMT1 could be a DLBCL therapeutic target due to its significant association with Ki-67.
AB - DNMT1 is a target of approved anti-cancer drugs including decitabine. However, the prognostic value of DNMT1 protein expression in R-CHOP-treated diffuse large B-cell lymphomas (DLBCLs) remains unexplored. Here we showed that DNMT1 was expressed in the majority of DLBCL cases (n = 209/230, 90.9%) with higher expression in germinal centre B-cell-like (GCB)-DLBCL subtype. Low and negative DNMT1 expression (20% cut-off, n = 33/230, 14.3%) was predictive of worse overall survival (OS; p < 0.001) and progression-free survival (PFS; p < 0.001). Nonetheless, of the 209 DNMT1 positive patients, 33% and 42% did not achieve 5-year OS and PFS, respectively, indicating that DNMT1 positive patients showed considerably heterogeneous outcomes. Moreover, DNMT1 was frequently expressed in mitotic cells and significantly correlated with Ki-67 or BCL6 expression (r = 0.60 or 0.44, respectively; p < 0.001). We demonstrate that DNMT1 is predictive of DLBCL patients' survival, and suggest that DNMT1 could be a DLBCL therapeutic target due to its significant association with Ki-67.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Antibodies, Monoclonal, Murine-Derived
KW - Antineoplastic Combined Chemotherapy Protocols
KW - B-Lymphocytes/pathology
KW - Biomarkers, Tumor/metabolism
KW - Cyclophosphamide
KW - DNA (Cytosine-5-)-Methyltransferase 1/metabolism
KW - Disease-Free Survival
KW - Doxorubicin
KW - Female
KW - Germinal Center/pathology
KW - Humans
KW - Ki-67 Antigen/metabolism
KW - Lymphoma, Large B-Cell, Diffuse/diagnosis
KW - Male
KW - Middle Aged
KW - Prednisone
KW - Prognosis
KW - Vincristine
KW - Young Adult
U2 - 10.1016/j.pathol.2017.08.009
DO - 10.1016/j.pathol.2017.08.009
M3 - Journal article
C2 - 29074044
VL - 49
SP - 731
EP - 739
JO - Pathology
JF - Pathology
SN - 0031-3025
IS - 7
ER -
ID: 197002467